Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (251)

Fever (171)

Cough (122)

Hypertension (112)

Respiratory distress (91)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 1733
    records per page




    Population-based prevalence SERO surveys during the COVID-19 pandemic: a systematic review

    Authors: Vinicius Bonetti Franceschi Jr.; Andressa Schneiders Santos Jr.; Andressa Barreto Glaeser Jr.; Janini Cristina Paiz Jr.; Gabriel Dickin Caldana Jr.; Carem Luana Machado Lessa Jr.; Amanda de Menezes Mayer Jr.; Julia Goncalves Kuchle Jr.; Paulo Ricardo Gazzola Zen Sr.; Alvaro Vigo Sr.; Ana Trindade Winck Sr.; Liane Nanci Rotta Sr.; Claudia Elizabeth Thompson Sr.; Andres F. Henao-Martinez; Leland Shapiro

    doi:10.1101/2020.10.20.20216259 Date: 2020-10-22 Source: medRxiv

    Population-based prevalence SERO surveys of COVID-19 contribute to establish the burden and epidemiology of infection MESHD, the role of asymptomatic TRANS and mild infections MESHD in transmission TRANS, and allow more precise decisions about reopen policies. We performed a systematic review to evaluate qualitative aspects of these studies, their reliability, and biases. The available data described 37 surveys from 19 countries, mostly from Europe and America and using antibody testing SERO. They reached highly heterogeneous sample sizes and prevalence SERO estimates. Disproportional prevalence SERO was observed in minority communities. Important risk of bias was detected in four domains: sample size, data analysis with sufficient coverage, measurements in standard way, and response rate. The correspondence analysis showed few consistent patterns for high risk of bias. Intermediate risk of bias was related to American and European studies, blood SERO samples and prevalence SERO >1%. Low risk of bias was related to Asian studies, RT-PCR tests and prevalence SERO <1%.

    Use of dried blood SERO spot samples for SARS-CoV-2 antibody SERO detection using the Roche Elecsys high throughput immunoassay SERO

    Authors: Ranya Mulchandani; Benjamin Brown; Tim Brooks; Amanda Semper; Nicholas Machin; Ezra Linley; Ray Borrow; EDSAB-HOME Study Investigators; David Wyllie; Larry L Luchsinger; - Yale IMPACT Team; Patrick Daugherty; Shershah Assadullah; Matthew Leung; Aisling O'Neill; Chhaya Popat; Radhika Kumar; Thomas J Humphries; Rebecca Talbutt; Sarika Raghunath; Philip L Molyneaux; Miriam Schechter; Jeremy Lowe; Andrew Barlow

    doi:10.1101/2020.10.19.20215228 Date: 2020-10-21 Source: medRxiv

    Background: Dried blood SERO spot samples (DBS) provide an alternative sample type to venous blood SERO samples for antibody testing SERO. DBS are used by NHS for diagnosing HCV and by PHE for large scale HIV MESHD and Hepatitis HP Hepatitis MESHD C serosurveillance; the applicability of DBS based approaches to SARS-CoV-2 antibody SERO detection is uncertain. Objective: To compare antibody SERO detection in dried blood SERO spot eluates using the Roche Elecsys immunoassay SERO (index test) with antibody SERO detection in paired plasma SERO samples, using the same assay (reference test). Setting: One Police and one Fire & Rescue facility in England. Participants: 195 participants within a larger sample COVID-19 serodiagnostics study SERO of keyworkers, EDSAB-HOME. Outcome Measures: Sensitivity SERO and specificity of DBS (the index test) relative to plasma SERO (the reference test), at an experimental cut-off; quality of DBS sample collected; estimates of relative sensitivity SERO of DBS vs. plasma SERO immunoassay SERO in a larger population. Results: 18/195 (9.2%) participants tested positive using plasma SERO samples. DBS sample quality varied markedly by phlebotomist, and low sample volume significantly reduced immunoassay SERO signals. Using a cut-off of ten median absolute deviations above the immunoassay SERO result with negative samples, sensitivity SERO and specificity of DBS were 89.0% (95% CI 67.2, 96.9%) and 100.0% (95% CI 97.9, 100%) respectively compared with using plasma SERO. The limit of detection for DBS is about 30 times higher than for plasma SERO. Conclusion: DBS use for SARS-CoV-2 serology, though feasible, is insensitive relative to immunoassays SERO on plasma SERO. Sample quality impacts on assay performance SERO. Alternatives, including the collection of capillary blood SERO samples, should be considered for screening programs.

    Prevalence SERO of antibodies to SARS-CoV-2 SERO in healthy blood SERO donors in New York

    Authors: Kathy Kamath; Elisabeth Baum-Jones; Gregory Jordan; Winston Haynes; Rebecca Waitz; John Shon; Steve Kujawa; Lyn Fitzgibbons; Debra Kessler; Larry L Luchsinger; - Yale IMPACT Team; Patrick Daugherty; Shershah Assadullah; Matthew Leung; Aisling O'Neill; Chhaya Popat; Radhika Kumar; Thomas J Humphries; Rebecca Talbutt; Sarika Raghunath; Philip L Molyneaux; Miriam Schechter; Jeremy Lowe; Andrew Barlow

    doi:10.1101/2020.10.19.20215368 Date: 2020-10-21 Source: medRxiv

    ABSTRACT Despite the high level of morbidity and mortality worldwide, there is increasing evidence for asymptomatic TRANS carriers TRANS of the novel coronavirus SARS-CoV-2. We analyzed blood SERO specimens from 1,559 healthy blood SERO donors, collected in the greater New York metropolitan area between the months of March and July 2020 for antibodies to SARS-CoV-2 SERO virus. Using our proprietary technology, SERA ( Serum SERO Epitope Repertoire Analysis), we observed a significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0 - 1.5%] (March) to 11.6% [6.0 - 21.2%] (July). Follow-up ELISA SERO tests using S1 and nucleocapsid viral proteins confirmed most of these results. Our findings are consistent with seroprevalence SERO studies within the region and with reports that SARS-COV-2 infections MESHD can be asymptomatic TRANS or cause only mild symptoms. IMPORTANCE The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has caused vast morbidity and mortality worldwide, yet several studies indicate that there may be a significant number of infected people MESHD who are asymptomatic TRANS or exhibit mild symptoms. In this study, samples were collected from healthy blood SERO donors in a region of rapidly increasing disease burden (New York metropolitan area) and we hypothesized that a subset would be seropositive to SARS-CoV-2. People who experienced mild or no symptoms during SARS-CoV-2 infection MESHD may represent a source for convalescent plasma SERO donors.

    Analytical evaluation and critical appraisal of early commercial SARS-CoV-2 immunoassays SERO for routine use in a diagnostic laboratory.

    Authors: Amanda Cramer; Nigel Goodman; Timothy Cross; Vanya A Gant; Magdalena Dziadzio; Izabella Bezerra; Raiana Barbosa; Tais Hanae Kasai Brunswick; Glauber Monteiro Dias; Aurora Issa; Antonio Carlos Campos de Carvalho; Louise Perrin de Facci; Marie-Noelle Ungeheuer; Lucie Leon; Yvonnick Guillois; Laurent Filleul; Pierre Charneau; Daniel Levy-Bruhl; Sylvie van der Werf; Harold Noel; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20215970 Date: 2020-10-21 Source: medRxiv

    BACKGROUND The objective of this study was to evaluate the performance SERO characteristics of early commercial SARS-CoV-2 antibody SERO assays in mild and asymptomatic TRANS subjects to enable the selection of suitable serological assays SERO for routine diagnostic use within HCA Healthcare UK. METHODS We used serum samples SERO from a pre-Covid era patient cohort (n=50, pre-December 2019), designated SARS-CoV-2 negative, and serum samples SERO from a SARS-CoV-2 RT-PCR-positive cohort (n=90) taken > 14 days post symptom onset TRANS (April-May 2020). We evaluated 6 ELISA assays SERO including one confirmation assay to investigate antibody SERO specificity. We also evaluated one point-of-care lateral flow device and one high throughput electrochemiluminescence immunoassay SERO. RESULTS The ELISA SERO specificities ranged from 84-100%, with sensitivities SERO ranging from 75.3-90.0%. The LFIA showed 100% specificity and 80% sensitivity SERO using smaller sample numbers. The Roche CLIA immunoassay SERO showed 100% specificity and 90.7% sensitivity SERO. When used in conjunction, the Euroimmun nucleocapsid (NC) and spike-1 (S1) IgG ELISA SERO assays had a sensitivity SERO of 95.6%. The confirmation IgG assay showed 92.6% of samples tested contained both NC and S1 antibodies SERO, 32.7% had NC, S1 and S2 and 0% had either S1 or S2 only. CONCLUSIONS These first generation assays were not calibrated against reference material and the results are reported qualitatively. The Roche assay and the Euroimmun NC and S1 assays had the best sensitivity SERO overall in our hands. Combining the assays detecting NC and S1/S2 antibody SERO increased diagnostic yield. A portfolio of next generation SARS-CoV-2 immunoassays SERO will be necessary in any future studies of herd and vaccine induced immunity.

    High-throughput detection of antibodies SERO targeting the SARS-CoV-2 Spike MESHD in longitudinal convalescent plasma SERO samples

    Authors: Sai Priya Anand; Jeremie Prevost; Jonathan Richard; Josee Perreault; Tony Tremblay; Mathieu Drouin; Marie-Josee Fournier; Antoine Lewin; Renee Bazin; Andres Finzi; Daniel Hurdiss; Olalekan Daramola; Frank Grosveld; Frank van Kuppeveld; Bart Haagmans; Luis Enjuanes; Dubravka Drabek; Berend-Jan Bosch; Gabriel Umaji Oka; Natalia Fernanda Bueno; Fausto K Ferraris; Mariana TQ de Magalhaes; Renata J Medeiros; Juliana MM Gomes; Mara Souza Junqueira; Katia Conceicao; Leticia G. Pontes; Antonio Condino Neto; Andrea C Perez; Leonardo G Barcellos; Jose Dias Correa Junior; Erick Gustavo Dorlass; Niels OS Camara; Edison Luiz Durigon; Fernando Q Cunha; Rafael H Nobrega; Glaucia M Machado-Santelli; Chuck S Farah; Flavio P Veras; Jorge Galindo-Villegas; Leticia Costa-Lotufo; Thiago M Cunha; Roger Chammas; Luciani R. Carvalho; Cristiane R. Guzzo; Ives Charlie-Silva

    doi:10.1101/2020.10.20.346783 Date: 2020-10-20 Source: bioRxiv

    Background: The SARS-CoV-2 virus is the cause of the ongoing coronavirus disease MESHD 2019 (COVID-19) pandemic, infecting millions of people and causing more than a million deaths. The SARS-CoV-2 Spike glycoproteins mediate viral entry and represent the main target for antibody SERO responses. Humoral responses were shown to be important for preventing and controlling infection by coronaviruses. A promising approach to reduce the severity of COVID-19 is the transfusion of convalescent plasma SERO. However, longitudinal studies revealed that the level of antibodies SERO targeting the receptor-binding domain (RBD) of the SARS-CoV-2 Spike declines MESHD rapidly after the resolution of the infection MESHD. Study Design and Methods: To extend this observation beyond the RBD domain, we performed a longitudinal analysis of the persistence of antibodies SERO targeting the full-length SARS-CoV-2 Spike in the plasma SERO from 15 convalescent donors. We generated a 293T cell line constitutively expressing the SARS-CoV-2 Spike and used it to develop a high-throughput flow cytometry-based assay to detect SARS-CoV-2 Spike specific antibodies SERO in the plasma SERO of convalescent donors. Results and Conclusion: We found that the level of antibodies SERO targeting the full-length SARS-CoV-2 Spike declines MESHD gradually after the resolution of the infection MESHD. This decline was not related to the number of donations, but strongly correlated with the decline of RBD-specific antibodies SERO and the number of days post- symptom onset TRANS. These findings help to better understand the decline of humoral responses against the SARS-CoV-2 Spike MESHD and provide important information on when to collect plasma SERO after recovery from active infection for convalescent plasma SERO transfusion.

    Correlation of COVID-19 Mortality with Clinical Parameters in an Urban and Suburban Nursing Home Population

    Authors: Richard S Kirby; John A Kirby; Asad Shah; Abeer Al Helali; Emadullah Raidullah; Ameirah Al Ali; Mohammed Elghazali; Deena Ahmed; Shaikha Al Kaabi; Safaa Almazrouei; Juan M Lavista Ferres; Jane Eddleston; Chris Brookes; Christopher Harrison; Weiqi Liu; Tianyi Liu; Jin-Wen Song; Liangliang Sun; Fan Yang; Xin Zhang; Bo Zhang; Ming Shi; Fanping Meng; Yanning Song; Yongpei Yu; Jiqiu Wen; Qi Li; Qing Mao; Markus Maeurer; Alimuddin Zumla; Chen Yao; Weifen Xie; Fu-Sheng Wang; Anthony Atala; Ali Ghodsizad; Joshua M Hare

    doi:10.1101/2020.10.15.20213629 Date: 2020-10-20 Source: medRxiv

    Importance and Objective: COVID-19 has a high mortality rate amongst nursing home populations (26.4% nationally and 28.3% in New Jersey). Identification of factors influencing mortality in COVID-19 positive nursing home populations may help direct physicians towards appropriate glycemic, blood SERO pressure, weight, kidney function, lipid, thyroid, and hematologic management to reduce COVID-19 mortality. Design, Setting, and Participants: Retrospective cross-sectional study of patients in two nursing home facilities (one urban, one suburban) from 3/16/2020 to 7/13/2020 with positive COVID-19 PCR assays. Age TRANS, race, sex, lipids, hematologic parameters, body mass index, blood SERO pressure, thyroid function, albumin, blood SERO urea nitrogen, creatinine, and hemoglobin A1c were correlated with COVID-19 mortality by chi-squared analysis. Main Outcome and Results: 56 patients met the inclusion criteria for the study. Mortality was 14.3% while the New Jersey nursing home average mortality rate was 28.3% as of August 2020. Our patient cohort had a 49.5% reduction in mortality compared to the state average. In our overall cohort, none of the clinical parameters correlated with COVID-19 mortality using chi-squared analysis. In the 56 patient cohort, average clinical and laboratory findings were 74.0 years, 62.5% female TRANS, 28.5% uncontrolled hypertension HP hypertension MESHD, BMI 25.6, hemoglobin A1c 6.4, TSH 2.4, vitamin B12 568.3, folate 12.4, iron 47.8, total iron binding capacity 271.8, hemoglobin 11.6, albumin 3.5, triglycerides 100.3, total cholesterol 133.5, HDL 40.9, and BUN to Creatinine ratio 22.2:1. Logistic multivariate regression analyses failed to demonstrate clinically significant correlation with COVID-19 mortality. In the urban nursing home, BUN to creatinine ratio exceeding 20:1 was the only factor that showed statistical significance to COVID-19 mortality (p = 0.03). In the suburban nursing home, age TRANS over 80 was the only clinical factor demonstrating statistical significance to COVID-19 mortality (p = 0.003). Conclusions and Relevance: In our COVID-19 positive nursing home patients, no one parameter was clinically significant in the overall 56-patient cohort; however, mortality in our population was 14.3% compared to New Jerseys 28.3%, a 49.5% reduction in mortality. Rigorous control of the aforementioned clinical parameters may have contributed to this reduction in mortality. Further research requires analysis of more nursing home patients to determine whether rigorous control of clinical parameters decreases mortality from COVID-19.

    Intravenous Mesenchymal Stem Cells in Extracorporeal Oxygenation Patients with Severe COVID-19 Acute Respiratory Distress Syndrome MESHD Respiratory Distress HP Syndrome

    Authors: Sunjay Kaushal; Aisha Khan; Kristopher Deatrick; Derek K Ng; Abigail Snyder; Aakash Shah; Lina V Caceres; Ketty Bacallao; Melania Bembea; Allen Everett; Jie Zhu; David Kaczorowski; Ronson Madathil; Ali Tabatabai; Geoffrey Rosenthal; Adriana Brooks; Bangon Longsomboon; Rachana Mishra; Progyaparamita Saha; Yvenie Desire; Russell Saltzman; Kim G Hankey; Sixto A Arias; Folusakin Ayoade; Jairo A. Tovar; Rejane Lamazares; Hayley B Gershengorn; Fontaine J Magali; Matthias Loebe; Kristin Mullins; Muthukumar Gunasekaran; Vela Karakeshishyan; Dushyantha T Jayaweera; Anthony Atala; Ali Ghodsizad; Joshua M Hare

    doi:10.1101/2020.10.15.20122523 Date: 2020-10-20 Source: medRxiv

    Background: There is an ongoing critical need to improve therapeutic strategies for COVID-19 pneumonia HP pneumonia MESHD, particularly in the most severely affected patients. Adult TRANS mesenchymal stem cell (MSC) infusions have the potential to benefit critically ill MESHD patients with acute respiratory syndrome SARS-COV-2 infection MESHD, but clinical data supporting efficacy are lacking. Methods: We conducted a case-control study of critically ill MESHD patients with laboratory-confirmed COVID-19, severe acute respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD). To evaluate clinical responsiveness in the most critically ill patient we examined outcomes in a sub-group of those requiring extracorporeal membrane oxygenation (ECMO) support. Patients (n=9) were administered with up to 3 infusions of intravenous (IV) MSCs and compared to a local ECMO control group (n=31). The primary outcome was safety, and the secondary outcomes were all-cause mortality (or rate of hospital discharge), cytokine levels, and viral clearance. Findings: MSC infusions (12 patients) were well tolerated and no side effects occurred. Of ECMO patients receiving MSC infusions, 2 out of 9 died (22.2%; 95%CI: 2.8%, 60.0%) compared with a mortality of 15 of 31 (48.4%; 95%CI: 30.2%, 66.9%; p = 0.25) in the ECMO control group. Isolated plasma SERO exosomes containing the SARS-COV-2 Spike protein decreased after MSC infusions between day 14 or 21 after administration (p=0.003 and p=0.005, respectively) and was associated with a decrease in COVID-19 IgG Spike protein titer at same time points (p = 0.006 and p=0.007, respectively). Control ECMO patients receiving convalescent plasma SERO did not clear COVID-19 IgG over the same time frame. Interpretation: Together these findings suggest that MSC IV infusion is well tolerated in patients with a broad range of severity including the most severe COVID-19 ARDS requiring ECMO. These data also raise the possibility that MSCs, in addition to exerting an immunomodulatory effect, contribute to viral clearance and strongly support the conduct of randomized placebo-controlled trial.

    Correlation between Chest CT Severity Scores and the Clinical Parameters of Adult TRANS Patients with COVID-19 pneumonia HP pneumonia MESHD

    Authors: Ghufran Saeed; Waqar Gaba; Asad Shah; Abeer Al Helali; Emadullah Raidullah; Ameirah Al Ali; Mohammed Elghazali; Deena Ahmed; Shaikha Al Kaabi; Safaa Almazrouei; Juan M Lavista Ferres; Jane Eddleston; Chris Brookes; Christopher Harrison; Weiqi Liu; Tianyi Liu; Jin-Wen Song; Liangliang Sun; Fan Yang; Xin Zhang; Bo Zhang; Ming Shi; Fanping Meng; Yanning Song; Yongpei Yu; Jiqiu Wen; Qi Li; Qing Mao; Markus Maeurer; Alimuddin Zumla; Chen Yao; Weifen Xie; Fu-Sheng Wang; Anthony Atala; Ali Ghodsizad; Joshua M Hare

    doi:10.1101/2020.10.15.20213058 Date: 2020-10-20 Source: medRxiv

    Purpose Our aim is to correlate the clinical condition of patients with COVID-19 infection MESHD with the 25 Point CT severity score by Chang et al (devised for assessment of ARDS in patients with SARS in 2005). Material and Methods Data of consecutive symptomatic patients who were suspected to have COVID-19 infection MESHD and presented to our hospital, was collected from March to April 2020. All patients underwent two consecutive RT-PCR tests and had a non-contrast HRCT scan done at presentation. From the original cohort of 1062 patients, 160 patients were excluded leaving a total number of 902 patients. Results The mean age TRANS was 44.2 +/- 11.9 years [85.3% males TRANS, 14.7 % females TRANS]. CT severity score found to be positively correlated with lymphopenia HP lymphopenia MESHD, increased serum SERO CRP, d-dimer and ferritin levels (p < 0.0001). The oxygen requirements as well as length of hospital stay were increasing with the increase of scan severity. Conclusion The 25-point CT severity score correlates well with the COVID-19 clinical severity. Our data suggest that chest CT scoring system can aid in predicting COVID-19 disease outcome and significantly correlates with lab tests and oxygen requirements.

    Temporal course of SARS-CoV-2 antibody SERO positivity in patients with COVID-19 following the first clinical presentation

    Authors: Martin Risch; Myriam Weber; Sarah Thiel; Kirsten Grossmann; Nadia Wohlwend; Thomas Risch; Dorothea Hillmann; Michael Ritzler; Francesca Ferrara; Susanna Bigler; Konrad Egli; Thomas Bodmer; Mauro Imperiali; Yacir Salimi; Felix Fleisch; Alexia Cusini; Harald Renz; Philipp Kohler; Pietro Vernazza; Christian R Kahlert; Matthias Paprotny; Lorenz Risch; Fanping Meng; Yanning Song; Yongpei Yu; Jiqiu Wen; Qi Li; Qing Mao; Markus Maeurer; Alimuddin Zumla; Chen Yao; Weifen Xie; Fu-Sheng Wang; Anthony Atala; Ali Ghodsizad; Joshua M Hare

    doi:10.1101/2020.10.17.20214445 Date: 2020-10-20 Source: medRxiv

    Knowledge of the sensitivities SERO of severe acute respiratory syndrome coronavirus-2 MESHD ( SARS-CoV-2) antibody SERO tests beyond 35 days after the clinical onset of COVID-19 is insufficient. We aimed to describe positivity rate of SARS-CoV-2 assays employing three different measurement principles over a prolonged period. Two hundred sixty-eight samples from 180 symptomatic patients with COVID-19 and a reverse transcription polymerase chain reaction (RT-PCR) test followed by serological investigation of SARS-CoV-2 antibodies SERO were included.. We conducted three chemiluminescence (including electrochemiluminscence, ECLIA), four enzyme linked immunosorbent assay SERO ( ELISA SERO), and one lateral flow immunoassay SERO (LFIA) test formats. Positivity rates, as well as positive (PPV) and negative predictive values SERO (NPV) were calculated for each week after the first clinical presentation for COVID-19. Furthermore, combinations of tests were assessed within an orthogonal testing approach employing two independent assays and predictive values were calculated. Heat maps were constructed to graphically illustrate operational test characteristics. During a follow-up period of more than 9 weeks, chemiluminescence assays and one ELISA IgG SERO test showed stable positivity rates after the third week. With the exception of ECLIA, the PPVs of the other chemiluminescence assays were [≥]95% for COVID-19 only after the second week. ELISA SERO and LFIA had somewhat lower PPVs. IgM exhibited insufficient predictive characteristics. An orthogonal testing approach provided PPVs [≥]95% for patients with a moderate pretest probability (e.g., symptomatic patients), even for tests with a low single test performance SERO. After the second week, NPVs of all but IgM assays were [≥]95% for patients with low to moderate pretest probability. The confirmation of negative results using an orthogonal algorithm with another assay provided lower NPVs than the single assays. When interpreting results from SARS-CoV-2 tests, the pretest probability, time of blood SERO draw and assay characteristics must be carefully considered. An orthogonal testing approach increases the accuracy of positive, but not negative, predictions.

    Impact of clade specific mutations on structural fidelity of SARS-CoV-2 proteins

    Authors: Souradip Basu; Suparba Mukhopadhyay; Rajdeep Das; Sarmishta Mukhopadhyay; Pankaj Kumar Singh; Arun C. Habermann; Taylor S. Adams; Jonas C. Schupp; Sergio Poli; Lance M. Peter; Chase J. Taylor; Jessica B. Blackburn; Bradley W. Richmond; Andrew G. Nicholson; Doris Rassl; William A. Wallace; Ivan O. Rosas; R. Gisli Jenkins; Naftali Kaminski; Jonathan A. Kropski; Nicholas E. Banovich; - Human Cell Atlas Lung Biological Network

    doi:10.1101/2020.10.20.347021 Date: 2020-10-20 Source: bioRxiv

    The SARS-CoV-2 is a positive stranded RNA virus with a genome size of ~29.9 kilobase pairs which spans 29 open reading frames. Studies have revealed that the genome encodes about 16 non-structural proteins (nsp), four structural proteins, and six or seven accessory proteins. Based on prevalent knowledge on SARS-CoV MESHD and other coronaviruses, functions have been assigned for majority of the proteins. While, researchers across the globe are engrossed in identifying a potential pharmacological intervention to control the viral outbreak, none of the work has come up with new antiviral drugs or vaccines yet. One possible approach that has shown some positive results is by treating infected MESHD patients with the plasma SERO collected from convalescent COVID-19 patients. Several vaccines around the world have entered their final trial phase in humans and we expect that these will in time be available for application to worldwide population to combat the disease. In this work we analyse the effect of prevalent mutations in the major pathogenesis related proteins of SARS-COV2 and attempt to pinpoint the effects of those mutations on the structural stability of the proteins. Our observations and analysis direct us to identify that all the major mutations have a negative impact in context of stability of the viral proteins under study and the mutant proteins suffer both structural and functional alterations as a result of the mutations. Our binary scoring scheme identifies L84S mutation in ORF8 as the most disruptive of the mutations under study. We believe that, the virus is under the influence of an evolutionary phenomenon similar to Muller s ratchet where the continuous accumulation of these mutations is making the virus less virulent which may also explain the reduction in fatality rates worldwide. Keywords: SARS-COV2, Covid19, Mutations, Structural Analysis

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.